N-(2-Cyanoethyl)tryptamine
pharmaceutical compound
N-(2-Cyanoethyl)tryptamine (CE-T) is a serotonin receptor modulator and possible psychedelic drug of the tryptamine family related to tryptamine (T). It is the N-(2-cyanoethyl) derivative of tryptamine.
The drug acts as a prodrug of tryptamine and hence is a non-selective serotonin receptor agonist and monoamine releasing agent similarly. It shows greatly sustained tryptamine levels and neurochemical effects in rodents compared to tryptamine itself however. Peak levels of tryptamine with CE-T in the brain were lower than tryptamine itself, whereas total exposure to tryptamine with CE-T in the brain was no different than with tryptamine itself in rodents. CE-T alters brain serotonin and dopamine levels similarly to tryptamine, whereas both drugs have limited effects on brain norepinephrine levels. It produces hypolocomotion in rodents similarly to the combination of tryptamine with a monoamine oxidase inhibitor (MAOI). However, whereas tryptamine was unable to produce hypolocomotion without an MAOI, CE-T showed hypolocomotion regardless of whether the MAOI clorgiline was co-administered.
CE-T was first described in the scientific literature by 1985.
“N-(2-Cyanoethyl)tryptamine” enters the record as pharmaceutical compound. Crown Archives preserves that source wording while asking what 2-Cyanoethyl, tryptamine and pharmaceutical can confirm, complicate or overturn.
Why this record matters
“N-(2-Cyanoethyl)tryptamine” is worth following because a concise public description often conceals a longer documentary argument. Here, 2-Cyanoethyl, tryptamine and pharmaceutical provides the most credible route into that argument.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Jul 31, 2026. The linked authority identifier is Q140196986. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1985.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “N-(2-Cyanoethyl)tryptamine”, its source revision and the description used here.
- Expand the search: follow N-(2-Cyanoethyl)tryptamine primary sources, N-(2-Cyanoethyl)tryptamine archive and 2-Cyanoethyl research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “N-(2-Cyanoethyl)tryptamine”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “N-(2-Cyanoethyl)tryptamine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.